Skip to main content
. 2022 Jul 26;11(15):4339. doi: 10.3390/jcm11154339

Figure 2.

Figure 2

HOMA-IR: Effect of Adherence to LGIMD and CEP on Hazard Ratio of Time-to-Event (Loss of MAFLD Diagnostic Criteria for the Whole Sample and Adherent Participants). HOMA-IR: Homeostatic Model Assessment for Insulin Resistance; MAFLD: Metabolic-Associated Fatty Liver Disease: MAFLD1; presence of hepatic steatosis in overweight/obese subjects; MAFLD3: presence of hepatic steatosis and type 2 diabetes mellitus.